Investors

Translating Science into Solutions for Individualized Patient Care

Biotheranostics is a commercial stage molecular diagnostics company focused on cancer. We have two high-value proprietary and uniquely differentiated tests on the market, focused on critical areas of unmet medical needs. We are entering a rapid-growth phase with increasingly diversified growth drivers.

Biotheranostics has entered a rapid-growth phase with increasingly diversified growth drivers.

Learn more about Biotheranostics and our high-value, proprietary product portfolio.

Download Our Investor Presentation

Contact Biotheranostics for more information on partnering with us:

molecular@biotheranostics.com

Client Services: (877) 886 6739

Fax: (858) 587 5874

In The News

Newly Published Data Expands Clinical Utility of Breast Cancer IndexSM to Include Early-Stage, ER+ Patients with Node Positive Disease
Biotheranostics today announced publication in the Clinical Cancer Research journal of a study evaluating performance of a Breast Cancer Index (BCI) that was specifically developed…
Breast Cancer IndexSM Identifies a subset of Clinically Low Risk Patients Who May Require Longer Therapy
A recent publication in npj Breast Cancer reports that Breast Cancer Index (BCI), a genomic test performed by Biotheranostics, Inc., identifies patients…
New Data Affirms Value of Breast Cancer Index (BCI) in Identification of Early Stage ER+ Breast Cancer Patients Appropriate for Extended Endocrine Therapy (EET)
Biotheranostics, Inc. today announced new data further demonstrating the importance of BCI in clinical practice. In a study of more than 14,000 cases…
Biotheranostics Appoints Don Hardison as New CEO
Biotheranostics, Inc., a growing molecular diagnostics company, today announced the appointment of Don Hardison as Chief Executive Officer…
View All